St Peter´s Tuberculosis Specialised Hospital/Global Health Committee, Addis Ababa, Ethiopia.
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Int J Tuberc Lung Dis. 2022 Aug 1;26(8):753-759. doi: 10.5588/ijtld.22.0073.
STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the WHO. The present paper analyses factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the Short regimen. This analysis is restricted to 253 participants allocated to the Short regimen and is based on the protocol-defined modified intention to treat (mITT) population. Multivariable Cox regression models were built using backwards elimination with an exit probability of = 0.157, equivalent to the Akaike Information Criterion, to identify factors independently associated with a definite or probable FoR event. Four baseline factors were identified as being significantly associated with the risk of definite or probable FoR (male sex, a heavily positive baseline smear grade, HIV co-infection and the presence of costophrenic obliteration). There was evidence of association of culture positivity at Week 8 and FoR in a second model and Week 16 smear positivity, presence of diabetes and of smoking in a third model. The factors associated with FoR outcomes identified in this analysis should be considered when determining the optimal shortened treatment regimen.
STREAM(标准化抗结核药物治疗方案)阶段 1 研究表明,与世界卫生组织推荐的长程方案相比,短程方案治疗利福平耐药结核病(RR-TB)的疗效非劣效。本文分析了接受短程方案的参与者中出现治疗失败或复发(FoR)的确定或可能因素。该分析仅限于分配到短程方案的 253 名参与者,并且基于方案定义的修改意向治疗(mITT)人群。使用向后消除法构建多变量 Cox 回归模型,退出概率为 = 0.157,相当于赤池信息量准则,以确定与确定或可能的 FoR 事件独立相关的因素。四个基线因素被确定为与确定或可能的 FoR 风险显著相关(男性、严重阳性基线涂片等级、HIV 合并感染和肋膈角闭塞)。在第二个模型中,第 8 周培养阳性与 FoR 存在关联的证据,在第三个模型中,第 16 周涂片阳性、糖尿病和吸烟的存在与 FoR 存在关联。在这项分析中确定的与 FoR 结局相关的因素应在确定最佳缩短治疗方案时考虑。